About ManagedLab

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium dolemue launti totam aperiam, eaque ipsa quae abillo. Invente veriatis et quasi.

Myovant to Seek FDA OK on Pill to Treat Advanced Prostate Cancer

Posted by |2019-11-19T19:32:42-08:00November 19th, 2019|

A drug candidate once shelved by Takeda Pharmaceutical (NYSE: TAK) has found new life within Roivant Sciences spinout Myovant as a potential once-daily oral hormone therapy for patients with advanced prostate cancer. The Brisbane, CA-based biotech company (MYSE: MYOV) reported Tuesday that the drug, relugolix, met the primary goal of a Phase 3 trial, lowering […]

Inozyme Pharma Names Pedro Huertas Chief Medical Officer

Posted by |2019-11-18T19:49:34-08:00November 18th, 2019|

Pedro Heurtas has joined Inozyme Pharma as chief medical officer, the same position he held most recently at Sentien Pharmaceuticals. His experience also includes positions at Eloxx Pharmaceuticals, Genzyme, Shire, and Amicus Therapeutics (NASDAQ: FOLD). In other moves, Boston-based Inozyme appointed Gus Khursigara its vice president of medical affairs and clinical operations, and Catherine Nestor […]

ResTORbio’s Respiratory Drug Flunks Phase 3 Test, Shattering Shares

Posted by |2019-11-18T02:30:07-08:00November 15th, 2019|

A resTORbio respiratory drug has failed a late-stage test, and the company is stopping further development of the compound for lung infections in elderly patients. In the first of two Phase 3 studies, ResTORbio on Friday released preliminary data showing that its drug, RTB101, did not beat a placebo. Though the Boston-based company won’t proceed […]

Daré to Add Microchip-Based Birth Control to Women’s Health Portfolio

Posted by |2019-11-14T23:00:38-08:00November 14th, 2019|

The list of activities our smartphones can control grows daily. Transfer money? It’s simple. Order groceries? That, too. Turn off the bedroom lights? Check. How about contraception? Advancing new forms of birth control is a central focus at Daré Bioscience (NASDAQ: DARE), a San Diego-based biopharma company that’s built a pipeline of experimental devices and […]

Calporta, Started by Avalon Ventures-GSK, Is Acquired by Merck

Posted by |2019-11-13T09:25:16-08:00November 13th, 2019|

Another of the biopharma startups created as part of a collaboration between San Diego investment firm Avalon Ventures and GlaxoSmithKline has been acquired—but not by GSK. Instead, the company, Calporta Therapeutics, is being absorbed by Merck (NYSE: MRK), which is interested in its preclinical work on potential treatments for lysosomal storage and neurodegenerative diseases, including […]

NIBR’s Raman Departs for Chief Biz Dev Role at Flagship Pioneering

Posted by |2019-11-12T15:07:34-08:00November 12th, 2019|

Prakash Raman has joined venture capital firm Flagship Pioneering in the newly created role of chief business development officer. Raman comes to Cambridge, MA-based Flagship from the Novartis Institutes for BioMedical Research (NIBR), where he was vice president and global head of business development and licensing. Flagship’s portfolio companies include epigenetics medicines developer Omega Therapeutics […]

TransEnterix CEO Pope Steps Down, Fernando Appointed Successor

Posted by |2019-11-11T12:40:08-08:00November 11th, 2019|

Todd Pope, president and CEO of TransEnterix (NYSE American: TRXC) since 2008, has stepped down. The Research Triangle Park, NC-based surgical robotics company promoted Anthony Fernando to take Pope’s place. Fernando had been TransEnterix’s chief operating officer and chief technology officer. Pope will continue to advise the company to help with the transition of his […]

Looking to Level Up in NASH, Novo Nordisk Licenses Ube Drug Candidate

Posted by |2019-11-11T02:30:11-08:00November 8th, 2019|

Danish diabetes giant Novo Nordisk took another step this week in its efforts to establish a presence in nonalcoholic steatohepatitis, or NASH, a metabolic disorder closely related to diabetes that is anticipated to become the leading cause of liver transplants in the US in coming years. The company Thursday announced it had inked a deal […]

Odylia Therapeutics Names Ashley Winslow Its Chief Scientific Officer

Posted by |2019-11-07T16:47:18-08:00November 7th, 2019|

Ashley Winslow is joining Atlanta, GA-based Odylia Therapeutics, a nonprofit organization that aims to accelerate the development of gene therapies for people with inherited retinal disease, as its chief scientific officer. Most recently she was the senior director of portfolio development and translational research at the Orphan Disease Center at the University of Pennsylvania; she […]

3 Changes We Should Make to Address the Gender Pay Gap in Medicine

Posted by |2019-11-06T12:00:20-08:00November 6th, 2019|

Women in medicine earn about 20 percent less than men. That is a problem for multiple reasons. It is, of course, not fair to the women who go through the same training and have the same skills as their male counterparts. Worse still, if well-qualified women are discouraged from entering the profession because of this […]

Why Steve Kafka Left Third Rock Ventures for Up-and-Comer Section 32

Posted by |2019-11-05T15:52:48-08:00November 5th, 2019|

Section 32, which invests in healthcare and life sciences companies with a technology component, has added a third managing partner. The small venture capital firm was started in San Diego about two years ago by Bill Maris, who, during his time at Google, founded and led its corporate venture capital arm, now part of parent […]

With $9.5M, Intrepida Bio Launches to Target Pancreatic Cancer & More

Posted by |2019-11-04T15:00:31-08:00November 4th, 2019|

Dauntless Pharmaceuticals formed in 2016, and its founders said the Sofinnova Ventures-backed firm planned to take a new approach to building biotechs. Instead of advancing a broad stable of early-stage drug candidates under the same roof, Dauntless aimed to set up each asset within its own company. The idea was that when it came time […]
Load More Posts